Our website uses cookies. We use cookies to remember settings and to help provide you with the best experience we can. We also use cookies to continuously improve our website by compiling visitor statistics. Read more about cookies

Thomas Blom

PhD Student
Thomas Blom
Thomas Blom

Diagostic and therapeutic use of MIBG in neuroblastoma

In this project the focus is on diagostic use of MIBG for imaging. We study the uptake and retention of MIBG in vitro in a panel of cell lines. The contribution of the norepinephrine transporter and the vesicular transporters are studied. Concordance and discordance of MIBG uptake in MIBG avid tumors will be evaluated with aim to elucidate underlying biological factors.

  • Correction to: [18F]mFBG PET‑CT for detection and localisation of neuroblastoma: a prospective pilot study (European Journal of Nuclear Medicine and Molecular Imaging, (2023), 50, 4, (1146-1157), 10.1007/s00259-022-06063-6)

    • apr. 2023
    • Atia, Samim, et al
    • European Journal of Nuclear Medicine and Molecular Imaging
  • [18F]mFBG PET-CT for detection and localisation of neuroblastoma: a prospective pilot study

    • jan. 2022
    • Atia, Samim, et al
    • European Journal of Nuclear Medicine and Molecular Imaging
  • Treatment-Related Toxicities During Anti-GD2 Immunotherapy in High-Risk Neuroblastoma Patients

    • feb. 2021
    • Thomas, Blom, et al
    • Frontiers in Oncology
  • Thrombocytopenia after meta-iodobenzylguanidine (MIBG) therapy in neuroblastoma patients may be caused by selective MIBG uptake via the serotonin transporter located on megakaryocytes

    • jan. 2021
    • Thomas, Blom, et al
    • EJNMMI Research
  • Selective serotonin reuptake inhibitors (SSRIs) prevent meta-iodobenzylguanidine (MIBG) uptake in platelets without affecting neuroblastoma tumor uptake

    • jan. 2020
    • Thomas, Blom, et al
    • EJNMMI Research
View all publications